21 CFR § 522.1083 - Gonadotropin releasing factor analog-diphtheria toxoid conjugate.

---
identifier: "/us/cfr/t21/s522.1083"
source: "ecfr"
legal_status: "authoritative_unofficial"
title: "21 CFR § 522.1083 - Gonadotropin releasing factor analog-diphtheria toxoid conjugate."
title_number: 21
title_name: "Food and Drugs"
section_number: "522.1083"
section_name: "Gonadotropin releasing factor analog-diphtheria toxoid conjugate."
chapter_name: "FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES"
subchapter_number: "E"
subchapter_name: "ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS"
part_number: "522"
part_name: "IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS"
positive_law: false
currency: "2026-04-05"
last_updated: "2026-04-05"
format_version: "1.1.0"
generator: "[email protected]"
authority: "21 U.S.C. 360b."
regulatory_source: "40 FR 13858, Mar. 27, 1975, unless otherwise noted."
cfr_part: "522"
---


# 522.1083 Gonadotropin releasing factor analog-diphtheria toxoid conjugate.

(a) *Specifications.* Each milliliter (mL) of solution contains 0.2 milligrams (mg) gonadotropin releasing factor analog-diphtheria toxoid conjugate.

(b) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.

(c) *Conditions of use in swine*—(1) *Amount.* Each intact male pig or gilt should receive two 2-mL (0.4 mg) doses by subcutaneous injection. Administer the first dose no earlier than 9 weeks of age. Administer the second dose at least 4 weeks after the first dose.

(2) *Indications for use*—(i) *Intact male pigs intended for slaughter:* For the temporary immunological castration (suppression of testicular function) and reduction of boar taint.

(ii) *Gilts intended for slaughter:* For the temporary suppression of estrus.

(3) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian. For reduction of boar taint, intact male pigs should be slaughtered no earlier than 3 weeks and no later than 10 weeks after the second dose.

[76 FR 27889, May 13, 2011, as amended at 77 FR 4227, Jan. 27, 2012; 79 FR 16189, Mar. 25, 2014; 85 FR 45308, July 28, 2020]